Currently, there are 290.26M common shares owned by the public and among those 287.13M shares have been available to trade.
The company’s stock has a 5-day price change of -12.63% and -24.19% over the past three months. OCGN shares are trading 28.71% year to date (YTD), with the 12-month market performance up to 82.11% higher. It has a 12-month low price of $0.37 and touched a high of $2.11 over the same period. OCGN has an average intraday trading volume of 4.14 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.55%, -19.37%, and -42.84% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ocugen Inc (NASDAQ: OCGN) shares accounts for 27.51% of the company’s 290.26M shares outstanding.
It has a market capitalization of $217.40M and a beta (3y monthly) value of 3.86. The earnings-per-share (ttm) stands at -$0.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.55% over the week and 6.61% over the month.
Earnings per share for the fiscal year are expected to increase by 22.12%, and -25.93% over the next financial year.
Looking at the support for the OCGN, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on October 15, 2024, with the firm’s price target at $4. Chardan Capital Markets coverage for the Ocugen Inc (OCGN) stock in a research note released on March 01, 2023 offered a Buy rating with a price target of $3.50. Mizuho was of a view on August 23, 2022 that the stock is Buy, while ROTH Capital gave the stock Buy rating on June 15, 2022, issuing a price target of $8. Cantor Fitzgerald on their part issued Overweight rating on June 02, 2022.
